SMS Pharmaceuticals Limited has informed the Exchange about Investments in Subsidiary Company by way of subscription towards Rights Issue
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
SMS Pharmaceuticals has invested Rs. 3 crore in its subsidiary SMS Peptides Private Limited by subscribing to 30 lakh equity shares of Rs. 10 each at par through a rights issue. This increases SMS Pharma's stake in SMS Peptides from 93% to 99.98%. The funds will be used to procure initial equipment and machinery to carry out R&D activities at the subsidiary. SMS Peptides was incorporated in November 2024, operates in the pharmaceutical industry, and is yet to commence business operations. The transaction is classified as a related party transaction and has been carried out at arm's length.
This is a relatively small capital infusion into a newly formed, pre-operations subsidiary focused on R&D. For shareholders, it means SMS Pharma is consolidating its ownership in a subsidiary that hasn't started generating revenue yet, so there is no immediate impact on earnings or stock price. The move signals the company's intent to expand into peptide-related R&D activities going forward.